Abstract
The proteasome is a multisubunit cytosolic protein complex responsible for degrading cytosolic proteins. Several studies have implicated its involvement in the processing of viral particles used for gene delivery, thereby limiting the efficiency of gene transfer. Peptide-based nonviral gene delivery systems are sufficiently similar to viral particles in their size and surface properties and thereby could also be recognized and metabolized by the proteasome. The present study utilized proteasome inhibitors (MG 115 and MG 132) to establish that peptide DNA condensates are metabolized by the proteasome, thereby limiting their gene transfer efficiency. Transfection of HepG2 or cystic fibrosis/T1 (CF/T1) cells with CWK18 DNA condensates in the presence of MG 115 or MG 132 resulted in significantly enhanced gene expression. MG 115 and MG 132 increased luciferase expression 30-fold in a dose-dependent manner in HepG2 and CF/T1. The enhanced gene expression correlated directly with proteasome inhibition, and was not the result of lysosomal enzyme inhibition. The enhanced transfection was specific for peptide DNA condensates, whereas Lipofectamine- and polyethylenimine-mediated gene transfer were significantly blocked. A series of novel gene transfer peptides containing intrinsic GA proteasome inhibitors (CWK18(GA)n, where n=4, 6, 8 and 10) were synthesized and found to inhibit the proteasome. The gene transfer efficiency mediated by these peptides in four different cell lines established that a GA repeat of four is sufficient to block the proteasome and significantly enhance the gene transfer. Together, these results implicate the proteasome as a previously undiscovered route of metabolism of peptide-based nonviral gene delivery systems and provide a rationale for the use of proteasome inhibition to increase gene transfer efficiency.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout









References
Liu D, Knapp JE . Hydrodynamics-based gene delivery. Curr Opin Mol Ther 2001; 3: 192–197.
Wiethoff CM, Middaugh CR . Barriers to nonviral gene delivery. J Pharm Sci 2003; 92: 203–217.
Glickman MH, Ciechanover A . The ubiquitin–proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 2002; 82: 373–428.
Dantuma NP, Masucci MG . Stabilization signals: a novel regulatory mechanism in the ubiquitin/proteasome system. FEBS Lett 2002; 529: 22–26.
Strous GJ, Govers R . The ubiquitin–proteasome system and endocytosis. J Cell Sci 1999; 112: 1417–1423.
Dunlop R . Recent developments in the intracellular degradation of oxidized proteins. Free Radic Biol Med 2002; 33: 894–906.
Carrard G, Bulteau AL, Petropoulos I, Friguet B . Impairment of proteasome structure and function in aging. Int J Biochem Cell Biol 2002; 34: 1461–1474.
Sakamoto KM . Ubiquitin-dependent proteolysis: its role in human diseases and the design of therapeutic strategies. Mol Gen Metab 2002; 77: 44–56.
Pagano M . Cell cycle regulation by the ubiquitin pathway. FASEB J 1997; 11: 1067–1075.
Goldberg AL . Functions of the proteasome: the lysis at the end of the tunnel. Science 1995; 268: 522–523.
Baumeister W, Cejka Z, Kania M, Seemuller E . The proteasome: a macromolecular assembly designed to confine proteolysis to a nanocompartment. Biol Chem 1997; 378: 121–130.
Wlodawer A . Proteasome: a complex protease with a new fold and a distinct mechanism. Structure 1995; 3: 417–420.
Dawson S et al. The 26S-proteasome: regulation and substration recognition. Mol Biol Rep 1997; 24: 39–44.
Rivett AJ, Mason GF, Murray RJ, Reidlinger J . Regulation of proteasome structure and function. Mol Biol Rep 1997; 24: 99–102.
Ben-Neriah Y . Regulatory functions of ubiquitination in the immune system. Nat Immun 2002; 3: 20–26.
Duan D et al. Endosomal processing limits gene transfer to polarized airway epithelia by adeno-associated virus. J Clin Invest 2000; 105: 1573–1587.
Goettsch S, Bayer P . Structural attributes in the conjugation of ubiquitin, SUMO and RUB to protein substrates. Front Biosci 2002; 7: a148–162.
McKenzie DL, Kwok KY, Rice KG . A potent new class of reductively activated peptide gene delivery agents. J Biol Chem 2000; 275: 9970–9977.
Bogyo M, Wang EW . Proteasome inhibitors: complex tools for a complex enzyme. Curr Top Microbiol Immunol 2002; 268: 185–208.
Meng L et al. Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc Natl Acad Sci USA 1999; 96: 10403–10408.
Almond JB, Cohen GM . The proteasome: a novel target for cancer chemotherapy. Leukemia 2002; 16: 433–443.
Adams J et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999; 59: 2615–2622.
Grimm LM et al. Proteasomes play an essential role in thymocyte apoptosis. EMBO 1996; 15: 3835–3844.
Levitskaya J et al. Inhibition of antigen processing by the internal repeat region of the Epstein–Barr virus nuclear antigen-1. Nature 1995; 375: 685–688.
Tanaka K, Tsurumi C . The 26S proteasome: subunits and functions. Mol Biol Rep 1997; 24: 3–11.
Douar AM, Poulard K, Stockholm D, Danos O . Intracellular trafficking of adeno-associated virus vectors: routing to the late endosomal compartment and proteasome degradation. J Virol 2001; 75: 1824–1833.
Adami RC, Rice KG . Metabolic stability of glutaraldehyde cross-linked peptide DNA condensates. J Pharm Sci 1999; 88: 739–746.
Adami RC et al. Stability of peptide-condensed plasmid dna formulations. J Pharm Sci 1998; 87: 678–683.
Levitskaya J et al. Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein–Barr virus nuclear antigen 1. Proc Natl Acad Sci USA 1997; 94: 12616–12621.
Dantuma NP, Sharipo A, Masucci MG . Avoiding proteasomal processing: the case of EBNA1. Curr Top Microbiol Immun 2002; 269: 23–36.
Dantuma NP et al. Inhibition of proteasomal degradation by the Gly-Ala repeat of Epstein–Barr virus is influenced by the length of the repeat and the strength of the degradation signal. Proc Natl Acad Sci USA 2000; 97: 8381–8385.
Wadhwa MS et al. Peptide-mediated gene delivery: influence of peptide structure on gene expression. Bioconjugate Chem 1997; 8: 81–88.
Mosmann T . Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immun Methods 1983; 65: 55–63.
Rodgers KJ, Dean RT . Assessment of proteasome activity in cell lysates and tissue homogenates using peptide substrates. Int J Biochem Cell Biol 2003; 35: 716–727.
Smith PK et al. Measurement of protein using bicinchoninic acid. Anal Biochem 1985; 150: 76–85.
Terebesi J, Kwok KY, Rice KG . Iodinated plasmid DNA as a tool for studying gene delivery. Anal Biochem 1998; 263: 120–123.
Acknowledgements
We gratefully acknowledge support for this work from a seed grant from the Cystic Fibrosis Foundation through The University of Iowa Center for Gene Therapy and from NIH DK066212.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kim, J., Chen, CP. & Rice, K. The proteasome metabolizes peptide-mediated nonviral gene delivery systems. Gene Ther 12, 1581–1590 (2005). https://doi.org/10.1038/sj.gt.3302575
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.gt.3302575
Keywords
- peptide-mediated gene delivery
- metabolism
- proteasome
- gene transfer
This article is cited by
-
Gene therapy progress and prospects: cystic fibrosis
Gene Therapy (2006)